Early studies of LIFR inhibitors suggest favorable safety profiles and pharmacokinetics as well as favorable decreases in tumorigenesis of breast (EC330 and EC359) and pancreatic (eLIFR-Fc, EC359) cancer cells in vitro [172,173,174]. This evidence concerns the gene LIFR and cancer.